What’s happening: Johnson & Johnson will stop its plan that would have required hospitals participating in the 340B drug discount program to purchase Stelara and Xarelto at full price and apply for a rebate instead of receiving full discounts upfront. What else to know: The Health Resources and Services Administration (HRSA) notified J&J it would...
This content is restricted to members.
